如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

Group 1 - The article reports on stock buybacks conducted by various companies on September 5, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent [1][2] - Tencent Holdings repurchased 913,000 shares for a total of 551 million, representing 0.558% of its total share capital [2] - Other notable companies involved in buybacks include China Hongqiao (01378) with 1.276 million shares repurchased for 31.57 million, and Midea Group (N23078) with 300,000 shares for 25.83 million [2] Group 2 - The total number of shares repurchased by China Hongqiao reached 146 million, accounting for 1.560% of its total share capital [2] - Midea Group's cumulative buyback for the year stands at 863,400 shares, which is 0.133% of its total share capital [2] - Other companies such as Yum China (09987) and MGM China (02282) also participated, with Yum China repurchasing 57,700 shares for 20.13 million and MGM China repurchasing 1 million shares for 15.78 million [2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年9月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫 ...

希玛医疗(03309)发布公告，该公司于2025年9月4日斥资35.5万港元回购18.8万股股份，每股回购价格为 1.87-1.9港元。 ...

智通财经APP讯，希玛医疗(03309)发布公告，该公司于2025年9月4日斥资35.5万港元回购18.8万股股 份，每股回购价格为1.87-1.9港元。 ...

格隆汇9月4日丨希玛医疗(03309.HK)公告，9月4日耗资35.5万港元回购18.8万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年9月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 希瑪醫療控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.1 | HKD | | 800,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.1 | HKD | | 800,000,000 | 本月底法定/註冊股本 ...

Core Viewpoint - Hema Medical (03309) reported a revenue increase of 2.4% year-on-year, driven by rising demand for ophthalmic medical services in Hong Kong, despite competitive pressures in Shenzhen affecting dental and ophthalmic service revenues [1] Financial Performance - Revenue for the first half of 2025 reached HKD 944 million, reflecting a year-on-year growth of 2.4% [1] - Profit attributable to equity holders amounted to HKD 49.94 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The growth in revenue was primarily attributed to increased demand for ophthalmic services in the Hong Kong market, which was partially offset by decreased revenues in Shenzhen due to intense competition in dental and ophthalmic services [1] Acquisition Announcement - Hema Medical announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]

Core Viewpoint - Hema Medical (03309) reported a 6.5% increase in stock price, reaching HKD 2.13, with a trading volume of HKD 6.7167 million following the release of its mid-year results for 2025 [1] Financial Performance - The company reported revenue of HKD 944 million for the first half of 2025, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The slight increase in revenue was attributed to rising demand for ophthalmic medical services in Hong Kong, which boosted revenue from ophthalmic services [1] - However, this growth was partially offset by a decline in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Acquisition Announcement - Hema Medical announced an agreement to acquire 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]